Kairos Pharma, LTD. (KAPA) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2025-12-30

Kairos Pharma, LTD. (KAPA) — no SEC Form 4 insider filings recorded in the last 90 days. 4 Form 8-K material event filings were reported by KAPA in the last 90 days. InsiderAlpha tracks every KAPA SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Kairos Pharma, LTD. (KAPA)

SEC CIK	0001962011

90-Day SEC Filing Activity

Form 8-K filings (90d)	4
Latest Form 4 filing	2025-12-30

Recent KAPA Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2025-10-08	Bae Hyun W.	Director	A — Grant or award	19.1K	$0.00	—	SEC
2025-10-08	Keyoung Hansoo Michael	Director	A — Grant or award	19.1K	$0.00	—	SEC
2025-10-08	Singhvi Rahul	Director	A — Grant or award	19.1K	$0.00	—	SEC
2025-10-08	Samuelson Doug	Chief Financial Officer	A — Grant or award	152.7K	$0.00	—	SEC
2025-10-08	Yu John S	CEO and Chairman	A — Grant or award	190.8K	$0.00	—	SEC
2025-10-08	Murali Ramachandran	VP of Research and Development	A — Grant or award	152.7K	$0.00	—	SEC
2025-10-08	Bhowmick Neil	Chief Scientific Officer	A — Grant or award	171.8K	$0.00	—	SEC
2025-09-16	Keyoung Hansoo Michael	Director	A — Grant or award	10.0K	$0.00	—	SEC
2025-09-16	Bae Hyun W.	Director	A — Grant or award	10.0K	$0.00	—	SEC
2024-11-25	Murali Ramachandran	VP of Research and Development	P — Open-market purchase	200	$1.59	$318	SEC
2024-11-22	Samuelson Doug	Chief Financial Officer	P — Open-market purchase	2.5K	$1.50	$4K	SEC
2024-11-20	Yu John S	CEO and Chairman	P — Open-market purchase	4.0K	$1.44	$6K	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Kairos Pharma, LTD. (KAPA). Updated in real time as new filings are submitted to the SEC.

Recent KAPA Form 8-K Material Events

2026-07-15 — Item 8.01, 9.01 [SEC]
2026-06-30 — Item 5.07 [SEC]
2026-06-04 — Item 8.01, 9.01 [SEC]
2026-05-18 — Item 8.01, 9.01 [SEC]
2026-03-02 — Item 1.01, 8.01, 9.01 · Acquisition · positive [SEC]
Kairos Pharma entered into a binding term sheet to acquire 100% of worldwide rights to CL-273, a reversible pan EGFR inhibitor for EGFR mutant non-small cell lung cancer, from Celyn Therapeutics. The consideration includes 16.5% equity stake, $15 million milestone upon FDA submis

Recent Insider Filings

2025-12-30 — Bhowmick Neil (Chief Scientific Officer)
2025-12-23 — Bae Hyun W. (Director)
2025-11-26 — Murali Ramachandran (VP of Research and Development)
2025-11-26 — Keyoung Hansoo Michael (Director)
2025-11-26 — Singhvi Rahul (Director)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in KAPA insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

KAPA Insider Trading — FAQ

What is the latest insider trade for KAPA?: Kairos Pharma, LTD. (KAPA) had 0 insider filings in the last 90 days, with the most recent on 2025-12-30. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying KAPA stock?: 0 insider purchases of KAPA were filed in the last 90 days.
How many insiders are selling KAPA stock?: 0 insider sales of KAPA were filed in the last 90 days.
Where can I see KAPA SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every KAPA SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live KAPA dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.